Loading...

BMEA BIOMEA FUSION INC US FDA Inspections 8-K Filing

BM F

BM

BIOMEA FUSION INC

(BMEA)

2023 8-K

Show Summary

Summary

Equity Offerings

Equity Offerings

Product Expansion

Financial Statements

Financial Results

Management Changes

Management Change

Clinical Trial Results

Preclinical Data Update

Financial Results

FDA Approval Update

Earnings Reports

Annual Meeting Voting Results

Other Special Situation

Earnings Reports

Earnings Reports

Presentation of Patient Coh...

Presentation at J.P. Morgan...

Earnings Reports

Earnings Reports

Product Updates

Earnings Reports

Earnings Reports

Underwriting Agreement

Clinical Trial Data Announc...

Financial Results Announcement

Press Release and Presentation

External Links:

Biomea Fusion, Inc. announced FDA clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia.

AI Assistant

BIOMEA FUSION INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.